Loomis, Sayles & Company
PTGX icon

Loomis, Sayles & Company’s Protagonist Therapeutics PTGX Stock Holding History

Loomis, Sayles & Company’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-536,920
Closed -$24.1M – 922
2021
Q2 		$24.1M Buy
+536,920
New +$17.7M 0.03% 278

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Loomis, Sayles & Company's PTGX Position: Q3 2021 in Review

Loomis, Sayles & Company sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 536,920 shares — an estimated $24.1M sold.

Loomis, Sayles & Company first reported a position in PTGX in Q2 2021 and held it in 1 quarter. The position peaked at $24.1M in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

  • Loomis, Sayles & Company reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 536,920 Protagonist Therapeutics shares in Q3 2021, an estimated $24.1M.
  • Loomis, Sayles & Company first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 1 quarter.
  • Loomis, Sayles & Company's Protagonist Therapeutics position peaked at $24.1M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Loomis, Sayles & Company's 13F filing for Q3 2021, filed 12 Nov 2021.